$NNVC
NANOVIRICIDES, INC.

2024 Q3 Form 10-K Financial Statement

#000141057824001650 Filed on September 27, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2024
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.209M
YoY Change 59.11%
% of Gross Profit
Research & Development $1.933M $1.182M $5.437M
YoY Change 31.8% -59.38% -14.94%
% of Gross Profit
Depreciation & Amortization $193.5K $190.6K $750.7K
YoY Change 3.47% 0.32% 1.55%
% of Gross Profit
Operating Expenses $3.168M $2.391M $8.516M
YoY Change 55.93% -35.02% -4.78%
Operating Profit -$3.168M -$8.516M
YoY Change 55.93% -4.78%
Interest Expense $35.37K
YoY Change -67.85%
% of Operating Profit
Other Income/Expense, Net $41.02K $222.0K
YoY Change -34.72% -37.46%
Pretax Income -$2.356M
YoY Change -34.01%
Income Tax
% Of Pretax Income
Net Earnings -$3.100M -$2.356M -$8.300M
YoY Change 55.0% -34.01% -3.49%
Net Earnings / Revenue
Basic Earnings Per Share -$0.23 -$0.70
Diluted Earnings Per Share -$0.23 -$0.19 -$0.70
COMMON SHARES
Basic Shares Outstanding 14.68M 11.81M 11.87M
Diluted Shares Outstanding 13.72M 11.87M

Balance Sheet

Concept 2024 Q3 2024 Q2 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.798M $4.798M
YoY Change -41.13% -41.13%
Cash & Equivalents $3.900M $4.800M $4.798M
Short-Term Investments
Other Short-Term Assets $172.7K $172.7K
YoY Change -42.42% -42.42%
Inventory
Prepaid Expenses $175.1K $172.7K
Receivables
Other Receivables
Total Short-Term Assets $4.041M $4.971M $4.971M
YoY Change -43.42% -41.14% -41.18%
LONG-TERM ASSETS
Property, Plant & Equipment $7.366M $7.512M $7.512M
YoY Change -7.09% -7.33% -7.37%
Goodwill
YoY Change
Intangibles $323.2K $325.3K
YoY Change -2.49% -2.48%
Long-Term Investments
YoY Change
Other Assets $14.56K $14.56K
YoY Change 45.6% 45.6%
Total Long-Term Assets $7.699M $7.852M $7.852M
YoY Change -6.95% -7.12% -7.07%
TOTAL ASSETS
Total Short-Term Assets $4.041M $4.971M $4.971M
Total Long-Term Assets $7.699M $7.852M $7.852M
Total Assets $11.74M $12.82M $12.82M
YoY Change -23.85% -24.12% -24.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.096M $1.096M
YoY Change 181.11% 181.11%
Accrued Expenses $283.3K $262.5K $262.5K
YoY Change -16.59% 82.57% 87.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.633M $1.359M $1.359M
YoY Change 72.17% 154.33% 156.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.633M $1.359M $1.359M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.633M $1.359M $1.359M
YoY Change -33.3% -33.19% -33.07%
SHAREHOLDERS EQUITY
Retained Earnings -$142.5M -$139.4M
YoY Change 7.1% 6.41%
Common Stock $140.00 $131.00
YoY Change 19.66% 12.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.11M $11.46M $11.46M
YoY Change
Total Liabilities & Shareholders Equity $11.74M $12.82M $12.82M
YoY Change -23.85% -24.12% -24.13%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2024
OPERATING ACTIVITIES
Net Income -$3.100M -$2.356M -$8.300M
YoY Change 55.0% -34.01% -3.49%
Depreciation, Depletion And Amortization $193.5K $190.6K $750.7K
YoY Change 3.47% 0.32% 1.55%
Cash From Operating Activities -$2.600M -$1.481M -$6.300M
YoY Change 116.67% -1.24% 10.53%
INVESTING ACTIVITIES
Capital Expenditures $46.76K $98.16K $156.6K
YoY Change 464.03% 3.2%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$46.76K -$98.16K -$156.6K
YoY Change 367.64% 3.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.710M 3.120M 3.120M
YoY Change -3391.59%
NET CHANGE
Cash From Operating Activities -2.600M -1.481M -6.300M
Cash From Investing Activities -46.76K -98.16K -156.6K
Cash From Financing Activities 1.710M 3.120M 3.120M
Net Change In Cash -936.6K 1.541M -3.337M
YoY Change -21.95% -202.7% -43.89%
FREE CASH FLOW
Cash From Operating Activities -$2.600M -$1.481M -$6.300M
Capital Expenditures $46.76K $98.16K $156.6K
Free Cash Flow -$2.647M -$1.579M -$6.457M
YoY Change 119.05% 5.3% 10.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Notes Payable Noncurrent Related Party Type Extensible Enumeration
NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0001379006
CY2024 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2024 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2024 dei Amendment Flag
AmendmentFlag
false
CY2024 dei Trading Symbol
TradingSymbol
NNVC
CY2024 dei Document Transition Report
DocumentTransitionReport
false
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024 dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
CY2023Q2 us-gaap Notes Payable Noncurrent Related Party Type Extensible Enumeration
NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11698497
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13144055
CY2024 dei Document Type
DocumentType
10-K
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
CY2024 dei Entity File Number
EntityFileNumber
001-36081
CY2024 dei Entity Registrant Name
EntityRegistrantName
NANOVIRICIDES, INC.
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0674577
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
1 CONTROLS DRIVE
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
SHELTON
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06484
CY2024 dei City Area Code
CityAreaCode
203
CY2024 dei Local Phone Number
LocalPhoneNumber
937-6137
CY2024 dei Security12b Title
Security12bTitle
COMMON STOCK, PAR VALUE $0.00001 PER SHARE
CY2024 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2024 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024 dei Entity Small Business
EntitySmallBusiness
true
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14677000
CY2023Q4 dei Entity Public Float
EntityPublicFloat
11354000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024 dei Auditor Firm
AuditorFirmId
274
CY2024 dei Auditor Name
AuditorName
EISNERAMPER LLP
CY2024 dei Auditor Location
AuditorLocation
Iselin, New Jersey
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4797778
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8149808
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
172742
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
295486
CY2024Q2 us-gaap Assets Current
AssetsCurrent
4970520
CY2023Q2 us-gaap Assets Current
AssetsCurrent
8445294
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7512463
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8106647
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
325308
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
333578
CY2024Q2 nnvc Service Agreements
ServiceAgreements
14562
CY2023Q2 nnvc Service Agreements
ServiceAgreements
14361
CY2024Q2 us-gaap Assets
Assets
12822853
CY2023Q2 us-gaap Assets
Assets
16899880
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
262467
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
143760
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1358776
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
534250
CY2023Q2 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
1500000
CY2024Q2 us-gaap Liabilities
Liabilities
1358776
CY2023Q2 us-gaap Liabilities
Liabilities
2034250
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13144055
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11698497
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
131
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
117
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
150838832
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
145946257
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-139374895
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131080749
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
11464077
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
14865630
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12822853
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16899880
CY2024 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5437297
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6392414
CY2024 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3078814
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2551054
CY2024 us-gaap Operating Expenses
OperatingExpenses
8516111
CY2023 us-gaap Operating Expenses
OperatingExpenses
8943468
CY2024 us-gaap Operating Income Loss
OperatingIncomeLoss
-8516111
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-8943468
CY2024 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
271773
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
355833
CY2024 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
49808
CY2023 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
938
CY2024 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
221965
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
354895
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-8294146
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8588573
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11871054
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11871054
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11626220
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11626220
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23082025
CY2023 nnvc Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued
SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued
56357
CY2023 nnvc Series Preferred Shares Value Issued During Period For License Agreement
SeriesPreferredSharesValueIssuedDuringPeriodForLicenseAgreement
156987
CY2023 nnvc Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One
StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne
108000
CY2023 nnvc Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services
StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices
1012
CY2023 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
4822
CY2023 nnvc Stock Issued For Payment Of Director Fees Value
StockIssuedForPaymentOfDirectorFeesValue
45000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8588573
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
14865630
CY2024 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
117314
CY2024 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3120037
CY2024 nnvc Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued
SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued
43245
CY2024 nnvc Series Preferred Stock Issued Upon Conversion Of Related Party Promissory Note
SeriesPreferredStockIssuedUponConversionOfRelatedPartyPromissoryNote
1500000
CY2024 nnvc Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One
StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne
131600
CY2024 nnvc Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services
StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices
563
CY2024 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
2340
CY2024 nnvc Adjustment To Additional Paid In Capital Forgiveness Of Interest On Debt By Related Party
AdjustmentToAdditionalPaidInCapitalForgivenessOfInterestOnDebtByRelatedParty
49808
CY2024 nnvc Stock Issued For Payment Of Director Fees Value
StockIssuedForPaymentOfDirectorFeesValue
45000
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-8294146
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
11464077
CY2024 us-gaap Profit Loss
ProfitLoss
-8294146
CY2023 us-gaap Profit Loss
ProfitLoss
-8588573
CY2024 nnvc Preferred Shares Issued As Compensation
PreferredSharesIssuedAsCompensation
43245
CY2023 nnvc Preferred Shares Issued As Compensation
PreferredSharesIssuedAsCompensation
56357
CY2023 nnvc Preferred Shares Issued For License Agreement
PreferredSharesIssuedForLicenseAgreement
156987
CY2024 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
178940
CY2023 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
157822
CY2024 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
563
CY2023 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
1012
CY2024 us-gaap Depreciation
Depreciation
750744
CY2023 us-gaap Depreciation
Depreciation
739259
CY2024 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8270
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8270
CY2024 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-122744
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-54535
CY2024 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
201
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-28079
CY2024 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
219213
CY2023 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
99096
CY2024 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
486605
CY2023 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
19037
CY2024 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
168516
CY2023 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
98068
CY2023 nnvc Increase Decrease In Other Non Current Liability Related Party
IncreaseDecreaseInOtherNonCurrentLiabilityRelatedParty
1500000
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6315507
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5670051
CY2024 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
156560
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
151712
CY2024 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-156560
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-151712
CY2023 nnvc Payment Of Loans Payable
PaymentOfLoansPayable
94788
CY2024 nnvc Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3120037
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3120037
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-94788
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3352030
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5916551
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8149808
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14066359
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4797778
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8149808
CY2023 us-gaap Interest Paid Net
InterestPaidNet
938
CY2024 nnvc Related Party Shares Issued To Note Payable
RelatedPartySharesIssuedToNotePayable
1500000
CY2024 nnvc Forgiveness Of Interest On Related Party Debt
ForgivenessOfInterestOnRelatedPartyDebt
49808
CY2024 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1 – Organization and Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">NanoViricides, Inc. (the “Company”) is a clinical stage nano-biopharmaceutical company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology. NanoViricides possesses its own facility that supports research and development and drug discovery, drug candidate optimization, cGMP-compliant drug substance manufacturing, cGMP-compliant manufacturing and packaging of drug products for human clinical trials, and early commercialization. The Company has several drugs in various stages of development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">NanoViricides, Inc. is domiciled under the laws of the State of Delaware, with its principal operations located in the State of Connecticut. The Company’s fiscal year begins on July 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> and ends on the next June 30<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> of the calendar year. The Company operates in one reportable business segment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company devotes substantially all its activity to advancing research and development, including efforts in connection with clinical trials. The Company’s lead drug candidate is the active pharmaceutical ingredient (API) NV-387. NV-387 is a uniquely broad-spectrum antiviral drug that has demonstrated strong activity in lethal lung infection animal model studies of Coronavirus, RSV, Influenza and even an Orthopoxvirus model for Smallpox and MPox. The Company plans on developing NV-387 first as a treatment of RSV infection in pediatric patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At present, NV-387 is undergoing a PhaseIa/Ib human clinical trial for safety and tolerability in healthy subjects for the treatment of COVID-19, sponsored by our licensee and collaborator in India, Karveer Meditech Private Limited (KMPL). The trial involved Phase Ia single-ascending dose and Phase Ib multiple ascending dose studies in healthy subjects. Subjects were sequestered upon enrollment in a dedicated ward of the hospital clinical trial site during treatment. All subjects have been discharged and follow-up visits have been completed as of approximately the end of December 2023. The results of this clinical trial were consistent with the results of a single-injection safety/tolerability study in rats performed in support of the clinical trial application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The clinical trial application for this clinical trial was submitted during the pandemic and a separate part of the clinical trial for the treatment of COVID patients with NV-387 was also proposed. This second part of the clinical trials was cancelled due to inability to find patients to enroll despite opening a second site. The second site was subsequently closed around April/May 2024. Meanwhile, data upload and crosschecking activities for the healthy subjects Phase Ia/Ib part have now been completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is now working on developing the necessary datasets, documentation, and clinical trial pathway and trial designs, for a Phase II clinical trial application for the use of NV-387 for the treatment of RSV infection, as the Phase Ia/Ib study progresses into the data analysis phase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company further plans on expanding the indications of NV-387 to other respiratory viral infections including Influenzas, Coronaviruses, and others. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, the Company has previously developed a clinical drug candidate, NV-HHV-1 formulated as skin cream, for the treatment of Shingles. The Company plans on taking NV-HHV-1 into human clinical trials, and further develop the HerpeCide™ program after engaging into clinical trials of NV-387 in Phase II for RSV and possibly for multiple indications, including Influenzas. In the HerpeCide program alone, the Company has drug candidates against at least five indications at different stages of development. The Company’s drug candidates against HSV-1 “cold sores” and HSV-2 “genital herpes” are in advanced pre-clinical studies and are expected to follow the shingles drug candidate into human clinical trials. In addition, the Company has drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), a related party substantially owned by Dr. Anil Diwan, to which the Company has broad, exclusive licenses. The licenses are to entire fields and not to specific compounds. In all, the Company has exclusive, worldwide licenses for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV-1 and HSV-2), Influenza and Asian Bird Flu Virus, Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis virus, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes (restated), Varicella Zoster Virus (“VZV”) infections (i.e. Shingles and Chickenpox), and SARS-CoV-2 infections. In all cases, the discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performed by TheraCour, a related party substantially owned by Dr. Anil Diwan, under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour. Milestone payments were made or are specified in certain of the license agreements, details of which have been disclosed at the time the agreements were entered into. The Company negotiates and licenses specific verticals of therapeutic applications from TheraCour if promising drug candidates are found in early research and development against a virus target. TheraCour has not denied any such licenses when requested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has executed a new Memorandum of Understanding with TheraCour by signing as of September 23, 2024 and becoming effective as of September 20, 2024, subsequent to the reported period, whereby the Company has obtained a right of first refusal for all antiviral drug developments including unlicensed ones, and has codified the process of development of drugs for unlicensed viral indications leading later to appropriate license agreements. The Parties have also agreed in this MoU that any cash milestone payments related to development activities, that are awardable, will become payable only upon the Company having sufficient revenue, thus extending the provisions previously incorporated in the Amendment to the COVID License Agreement, to all present and future license agreements. This removes any potential cash flow stress that may occur due to such milestone payments while the Company continues its developments while not raising profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has out-licensed NV-CoV-2 and NV-CoV-2-R for further clinical drug development and commercialization in the territory of India to KMPL, a company of which Dr. Anil Diwan is a passive investor and advisor. KMPL has sponsored NV-CoV-2 for human clinical trials and has obtained regulatory approvals in India. KMPL has retained a local clinical research organization (CRO) to conduct the clinical trials. NV-CoV-2, Phase Ia/Ib human clinical trials in India, sponsored by KMPL began on June 17, 2023. The clinical trial drug products, NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, were manufactured at the Company’s Shelton campus, and then shipped to and received by KMPL. Under the agreement with KMPL, the Company will pay for the expenses of the clinical trials, and in return will benefit from having the data and reports made available for regulatory filings in other territories of the world. Upon commercialization, the Company will receive royalties from KMPL equal to 70% of sales net of costs to unaffiliated third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p>
CY2024 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024 nnvc Percentage Of Royalties On Sales
PercentageOfRoyaltiesOnSales
0.70
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-139400000
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-8300000
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6300000
CY2024 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4798000
CY2024Q2 us-gaap Liabilities
Liabilities
1359000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
262000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4800000
CY2024Q2 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
3000000
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheet and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for but not limited to, accounting for share-based compensation. Actual results could differ from those estimates.</p>
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concentrations of Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in FDIC or SIPC insured institutions in excess of federally insured limits under the FDIC. Although the Company currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the fiscal years ended June 30, 2024 and 2023.</p>
CY2024 us-gaap Interest Expense Debt
InterestExpenseDebt
49808
CY2024Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
8168045
CY2023Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
8168045
CY2024Q2 us-gaap Land
Land
260000
CY2023Q2 us-gaap Land
Land
260000
CY2024Q2 nnvc Office Equipment Gross
OfficeEquipmentGross
63056
CY2023Q2 nnvc Office Equipment Gross
OfficeEquipmentGross
60347
CY2024Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
5607
CY2023Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
5607
CY2024Q2 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
6469578
CY2023Q2 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
6315727
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14966286
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14809726
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7453823
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6703079
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7512463
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8106647
CY2024 us-gaap Depreciation
Depreciation
750744
CY2023 us-gaap Depreciation
Depreciation
739259
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
458954
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
458954
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
133646
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
125376
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
325308
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
333578
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23532
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
39060
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
11500
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4700
CY2024Q2 nnvc Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
227435
CY2023Q2 nnvc Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
100000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
262467
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
143760
CY2024 us-gaap Interest Expense Debt
InterestExpenseDebt
49808
CY2024 nnvc Number Of Common Stock To Be Issued Upon Conversion Of Warrants
NumberOfCommonStockToBeIssuedUponConversionOfWarrants
1144
CY2024 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
563
CY2023Q2 nnvc Adjustments To Additional Paid In Capital For Redomiciliation
AdjustmentsToAdditionalPaidInCapitalForRedomiciliation
11596
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
44000
CY2024 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2024 nnvc Percentage Of Us Federal Income Tax Rate
PercentageOfUsFederalIncomeTaxRate
0.21
CY2023 nnvc Percentage Of Us Federal Income Tax Rate
PercentageOfUsFederalIncomeTaxRate
0.21
CY2024 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2024 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0345
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0110
CY2024 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0593
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0593
CY2024 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0095
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0065
CY2024 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.2443
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.2648
CY2024 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
29351534
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27960157
CY2024Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8154686
CY2023Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
7868816
CY2024Q2 nnvc Deferred Tax Assets Tax Credit Carryforwards Research Expenses Capitalized
DeferredTaxAssetsTaxCreditCarryforwardsResearchExpensesCapitalized
2243662
CY2023Q2 nnvc Deferred Tax Assets Tax Credit Carryforwards Research Expenses Capitalized
DeferredTaxAssetsTaxCreditCarryforwardsResearchExpensesCapitalized
1536679
CY2024Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
22087
CY2023Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
25194
CY2024Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
39771969
CY2023Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
37390846
CY2024Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39771969
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
37390846
CY2024Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2024Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39771969
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
37390846
CY2024Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
109000000
CY2024Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
109000000
CY2023 nnvc Operating Loss That Can Be Carried Forward Indefinitely
OperatingLossThatCanBeCarriedForwardIndefinitely
8100000
CY2024 nnvc Operating Loss That Can Be Carried Forward Indefinitely
OperatingLossThatCanBeCarriedForwardIndefinitely
8100000
CY2018 nnvc Net Operating Losses Incurred In Income Tax Payable Net
NetOperatingLossesIncurredInIncomeTaxPayableNet
0.80

Files In Submission

Name View Source Status
0001410578-24-001650-index-headers.html Edgar Link pending
0001410578-24-001650-index.html Edgar Link pending
0001410578-24-001650.txt Edgar Link pending
0001410578-24-001650-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nnvc-20240630.xsd Edgar Link pending
nnvc-20240630x10k.htm Edgar Link pending
nnvc-20240630xex10d34.htm Edgar Link pending
nnvc-20240630xex19d1.htm Edgar Link pending
nnvc-20240630xex23.htm Edgar Link pending
nnvc-20240630xex31d1.htm Edgar Link pending
nnvc-20240630xex31d2.htm Edgar Link pending
nnvc-20240630xex32d1.htm Edgar Link pending
nnvc-20240630xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
nnvc-20240630_cal.xml Edgar Link unprocessable
nnvc-20240630_def.xml Edgar Link unprocessable
nnvc-20240630_lab.xml Edgar Link unprocessable
nnvc-20240630_pre.xml Edgar Link unprocessable
nnvc-20240630x10k_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable